# Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects

Study · id `cardio:ct-nct06471543` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06471543](<https://clinicaltrials.gov/study/NCT06471543>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06471543

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 108 participants.

## Technical summary

Registry record NCT06471543. Randomized; quadruple masking; primary purpose treatment. Start 2024-09-30 (actual); primary completion 2026-06-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 108 participants (planned count; ClinicalTrials.gov record NCT06471543, source copy `cardio:ctgov-nct06471543-2025-12-30`, retrieved 2026-10-31)
- Started: 2024-09-30 (actual) (ClinicalTrials.gov record NCT06471543, source copy `cardio:ctgov-nct06471543-2025-12-30`, retrieved 2026-10-31)
- Primary completion: 2026-06-03 (anticipated) (ClinicalTrials.gov record NCT06471543, source copy `cardio:ctgov-nct06471543-2025-12-30`, retrieved 2026-10-31)
- Completion: 2026-08-26 (anticipated) (ClinicalTrials.gov record NCT06471543, source copy `cardio:ctgov-nct06471543-2025-12-30`, retrieved 2026-10-31)
- Countries: United States; Australia (ClinicalTrials.gov record NCT06471543, source copy `cardio:ctgov-nct06471543-2025-12-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06471543-2025-12-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects
- Condition: Hypertriglyceridemia
- Condition: Familial Chylomicronemia Syndrome
- Intervention (Drug): RN0361
- Lead sponsor: Ikaria Bioscience Pty Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)

## Provenance

Content hash: 1698993c3533aa9cb09d0b0383dae5e43b57ed982e7f8cd22174af8685f83535
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
